Grécia - grego - Εθνικός Οργανισμός Φαρμάκων

ceva sante animale, libourne, france (0000006753) zi la ballastiere,,,33500 libourne,fr - inactivated coxiella burnetii, strain nine mile - ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - inactivated coxiella burnetii, strain nine mile 72,00 inj.susp 0 - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - Αίγες; Βοοειδή - Χρόνοι αναμονής: Βοοειδή 0 Ημέρες Κρέας και εδώδιμοι ιστοί, γάλα; Αίγες 0 Ημέρες Κρέας και εδώδιμοι ιστοί, γάλα

Grécia - grego - Εθνικός Οργανισμός Φαρμάκων

lab. hipra s.a., amer-girona, spain (0000007652) avda la selva, 135,e-17170,amer,es - inactivated rabbit haemorrhagic disease type 2 virus (rhdv2), strain v-1037 - ΕΝΕΣΙΜΟ ΓΑΛΑΚΤΩΜΑ - inactivated rabbit haemorrhagic disease type 2 virus (rhdv2), strain v-1037 70,00 em.inj 0 - inactivated viral vaccines - Κουνέλια - Χρόνοι αναμονής: Κουνέλια 0 Ημέρες Κρέας και εδώδιμοι ιστοί

Grécia - grego - Εθνικός Οργανισμός Φαρμάκων

zoetis belgium s.a., louvain-la-neuve, belgium (0000011199) rue laid burniat 1,1348,louvain-la-neuve,be - inactivated bluetongue virus , serotype 4, strain spa-1/2004 - ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - btv-4 - inactivated bluetongue virus , serotype 4, strain spa-1/2004 0,00 inj.susp btv-4 - inactivated viral vaccines - Πρόβατα; Βοοειδή - Χρόνοι αναμονής: Βοοειδή 0 Ημέρες Κρέας και εδώδιμοι ιστοί; Πρόβατα 0 Ημέρες Κρέας και εδώδιμοι ιστοί

Grécia - grego - Εθνικός Οργανισμός Φαρμάκων

zoetis belgium s.a., louvain-la-neuve, belgium (0000011199) rue laid burniat 1,1348,louvain-la-neuve,be - inactivated bluetongue virus , serotype 8, strain btv-8/bel2006/02 - ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - btv-8 - inactivated bluetongue virus , serotype 8, strain btv-8/bel2006/02 0,00 inj.susp btv-8 - inactivated viral vaccines - Βοοειδή; Πρόβατα - Χρόνοι αναμονής: Βοοειδή 0 Ημέρες Κρέας και εδώδιμοι ιστοί; Πρόβατα 0 Ημέρες Κρέας και εδώδιμοι ιστοί

Grécia - grego - Εθνικός Οργανισμός Φαρμάκων

zoetis belgium s.a., louvain-la-neuve, belgium (0000011199) rue laid burniat 1,1348,louvain-la-neuve,be - inactivated mycoplasma hyopneumoniae, strain p-5722-3; inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - ΕΝΕΣΙΜΟ ΓΑΛΑΚΤΩΜΑ - inactivated mycoplasma hyopneumoniae, strain p-5722-3 1,50 em.inj 0; inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein 2,30 em.inj 0 - inactivated viral and inactivated bacterial vaccines - Παχυνόμενοι χοίροι - Χρόνοι αναμονής: Παχυνόμενοι χοίροι 0 Ημέρες Κρέας και εδώδιμοι ιστοί

Grécia - grego - Εθνικός Οργανισμός Φαρμάκων

boehringer ingelheim vetmedica gmbh, ingelheim am rhein, germany (0000003115) -,55216,ingelheim/rhein,de - inactivated feline calicivirus (fcv 431 and g1 strains) antigens; attenuated feline rhinotracheitis herpesvirus (fhv f2 strain) - ΛΥΟΦΙΛΟΠΟΙΗΜΕΝΟ ΥΛΙΚΟ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - inactivated feline calicivirus (fcv 431 and g1 strains) antigens 2,00 ly.insp.sv 0; attenuated feline rhinotracheitis herpesvirus (fhv f2 strain) 0,00 ly.insp.sv 0 - live feline rhinotracheitis virus + inactivated feline calicivirus antigen - Γάτες - Χρόνοι αναμονής: Γάτες

União Europeia - grego - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - Ανοσολογικά για αιλουροειδών, - Γάτες - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

União Europeia - grego - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - Ανοσολογικά για αιλουροειδών, - Γάτες - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

União Europeia - grego - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - Ανοσολογικά για αιλουροειδών, - Γάτες - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. Τα αντισώματα ανοσίας έχουν αποδειχθεί 1 εβδομάδα μετά τον κύριο εμβολιασμό για ρινοτραχειίτιδα, καλυκοϊό και συστατικά chlamydophila felis. Η διάρκεια της ανοσίας είναι 1 έτος μετά τον τελευταίο (επαν) εμβολιασμό.

União Europeia - grego - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - Ανοσολογικά για αιλουροειδών, - Γάτες - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. Οι αντιδράσεις ανοσίας έχουν αποδειχθεί μία εβδομάδα μετά την αρχική πορεία εμβολιασμού για ρινοτραχειίτιδα, καλυκοϊό, συστατικά chlamydophila felis και παγκρεακοπενία. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.